Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/12—Ketones
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
  • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
  • C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C251/06—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
  • C07C251/08—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton being acyclic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/06—Antibacterial agents for tuberculosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/08—Antibacterial agents for leprosy
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• Present invention refers to the new biologically active polyimino ketoaldehyde compounds of and their antibacterial properties, pharmaceutical preparations containing compounds of poly(imino) ketoaldehydes as an active substance, their use in the treatment of bacterial infections and their preparation process.
• Polyimino ketoaldehydes are, according to the present invention, compounds with general formula I:
• ni is the number of carbon atoms connected to nitrogen atom by a double bond and can take values between 25 and 41
• n 2 is the number of -CH 2 - groups and can take values between 15 and 23, as well as their biologically acceptable salts and solvates.
• _ni can take values 25, 33, or 41
• n 2 can take values 15, 19, or 23, as well as their biologically acceptable salts and/or solvates.
• the present invention relates to the compound with the formula:
• ni has a value of 33, and n 2 a value of 19.
• the substrate can be selected from the group consisting of glycine, L-alanine, L-valine, L-leucine, 2-aminobutyric acid, 4- metiltreonin and D-alanine
• the enzyme is selected from a group consisting of cyclosporine-A synthetase (hereinafter: cAs), nonribosomal peptide synthetase 1 (hereinafter: NRPS l).
• the biotransformation itself occurs in the following phases:
• esterified amino acids are joined together in a way that results in the creation of a compound with general formula I.
• the adenylade domain forms acyl-adenylate substrate which uses a covalent bond to join substrate molecule to phosphopantetheine thus forming a cross-linked thioester which further transforms into a compound with general formula I, in particular l-amino-tetratriacontyl- henicosa-20-on-21 -al in the form of white precipitate which is purified by alternate washing in acid and water.
• adenosine triphosphate Mg 2+ was used as a cofactor.
• the cofactor is added in the reaction mixture in the form of magnesium sulphate with halogen or chalcogen elements.
• a buffer for the suspension of enzymes is also necessary, which is used for keeping the pH -level of the reaction mixture within the neutral range, i.e. within a pH range between 6 and 7.
• the appropriate buffer is any buffer that maintains the pH value within the stated range, for example acetate buffer.
• the reaction for obtaining the compound with general formula 1 is performed in the manner that the buffered components of reaction mixture consisting of Mg 2+ , ATP and substrates are mixed in the acetate buffer in a reactor, and the reaction is initiated by adding the enzyme suspension to the buffer.
• the reaction is performed at room temperature, i.e. at a temperature between 18 °C and 30 °C or, ideally, between 23 °C and 28 °C.
• the preferred temperature for the execution of the procedure for obtaining a compound with general formula I is 27 °C.
• pH value is continuously measured with a pH meter and , if necessary, maintained at optimal pH conditions with basis such as water solution of NaOH.
• the reaction is stoped with acid water solution, after which the reaction mixture cools down. During the cooling period, a white precipitate is formed which is washed with acid and water alternately.
• the second aspect of the invention concerns the pharmaceutical composition which contains an active amount of the compound with general formula I or its pharmaceutically acceptable salts and solvates in pharmaceutical variant that is appropriate for parenteral use, oral administration and intravenous use.
• the pharmaceutical composition can contain one or more pharmaceutically acceptable excipients such as carriers, lubricants, glidants, dyes, fillers, i.e. binders, disintegrants and surfactants.
• the pharmaceutical preparation can be compressed to give pellets, granules, tablets, blisters, capsules, tablets with controlled release of active substance. All pharmaceutical preparations, apart from the active substance, can contain pharmaceutically acceptable excipients. Excipients can be selected from a group of carriers, binders, fillers, surfactants, disintegrants, glidants, lubricants and other known pharmaceutically acceptable excipients.
• Carriers are selected from a group of known pharmaceutically acceptable carriers such as protein nanoparticles, polypeptides, liposomes, polymeric micelles, microspheres and mixtures of two or more known carriers.
• carriers are for illustrative purposes only and the selection of carriers is in no way limited to the above examples or their mixtures.
• Binders -fillers are selected from a group of known pharmaceutically acceptable binders- fillers such as sucrose, lactose, starch, cellulose, mannitol, sorbitol, xylitol, microcrystalline cellulose, siliconized microcrystalline cellulose, calcium hydrogen phosphate, calcium carbonate, calcium lactate and mixtures of two or more known pharmaceutically acceptable binders-fillers.
• binders-fillers are for illustrative purposes only and the selection of binders-fillers is in no way limited to the above examples or their mixtures.
• Surfactants are selected from a group of known pharmaceutically acceptable surfactants such as fatty acid esters, polysorbates, polyoxyethylene alkyl ethers, polyoxamers, triglycerides, polyoxylglycerides or mixtures of two or more known pharmaceutically acceptable surfactants.
• the above examples of surfactants are for illustrative purposes only and the selection of surfactants is in no way limited to the above examples or their mixtures.
• Disintegrants are selected from a group of known pharmaceutically acceptable disintegrants such as cross-linked polymers, for example carboxymethyl cellulose, polyvinylpyrrolidone or mixtures thereof.
• the above examples of disintegrants are for illustrative purposes only and the selection of disintegrants is in no way limited to the above examples or their mixtures.
• Glidants and lubricants are selected from a group of pharmaceutically known glidants and lubricants such as talc, silica powder, magnesium carbonate, magnesium stearate, or a mixture of two or more known pharmaceutically acceptable glidants and lubricant.
• glidants and lubricants are for illustrative purposes and the selection of glidants and lubricants is in no way limited to the above examples or their mixtures.
• composition according to the invention has the following composition:
• Example 1 preparation of l-amino-tetratriacontyl-henicosa-20-on-21-al
• 0.1 mol/L of acetate buffer is prepared by mixing 0.1 mol /L aqueous octenic acid solution with 0.1 mol/1 aqueous NaOH solution. The resulting solution has a pH of 6.
• NRPS l suspension was prepared in acetate buffer. Final NRPS l concentration in suspension amounted to 0.06 g/L.
• reaction flask 0.51 g of glycine, 0.85 g of MgCl 2 , 0.043 g of ATP was added to the reaction flask with magnetic stirrer and the mixture was dissolved in 85 mL of previously prepared acetate buffer. Reaction is initiated by adding 85 ⁇ of NRPS l suspension to the reaction flask. The temperature at which the reaction occurred was 27 °C. The stirring rate of the magnetic stirrer amounted to 500 spins/min, and the reaction time was 120 min. The reaction was stopped by admixing 85 mL 7% v/v water solution of trichloroacetic acid (ratio of reaction mixture and acid is 1 : 1). The reaction vessel was then placed on ice for 30 minutes.
• the calculated peak was supposed to appear at 445.50 m/z, and the observed peak was at 445.6564 inferring that the characteristic peak for compound 1- amino-tetratriacontyl-henicosa-20-on-21 -al is at 445.7959 with mass measurement error within the accuracy limits at 5 ppm - see picture 1.
• Example 2 composition of oral preparation Excipients in this example are hypromellose, microcrystalline cellulose, dye, titanium dioxide.
• the following invention aspect concerns antibacterial activity of the compound with general formula I
• the compound with general formula 1 demonstrates antibacterial properties against the following bacteria: Neisseria gonorrhoea, acinetobacter baumannii, staphylococcus aureus (MRSA, burkholderia cepaci, pseudomonas aeruginos, Clostridium difficil, escherichia coli (E. coli ESBL, mycobacterium tuberculosis, klebsiella pneumoniae, streptococcus pyogenes.
• MRSA staphylococcus aureus
• E. coli ESBL mycobacterium tuberculosis
• klebsiella pneumoniae streptococcus pyogenes.
• Table 1 shows inhibition zones for Avian Pathogenic Escherichia coli multi-resistant strain against l -amino-tetratriacontyl-henicosa-20-on-21 - al, Amoxicillin, Trimethoprim sulphate, tetracycline and Sulfadimidine.
• Table 1 contains the results for inhibition diameter expressed in mm.
• Table 2 shows minimal concentration of l-amino-tetratriacontyl-henicosa-20-on-21-al expressed in mg/mL that is necessary for the inhibition of Avian Pathogenic Escherichia coli multi- resistant strain.
• 1 -amino-tetratriacontyl- henicosa-20-on-21 -al is marked in tables as Cm.
• Antibiotics from Table 1 are administered in their standard dose for this type of testing. It is evident that only l -amino-tetratriacontyl-henicosa-20-on-2 1 -al shows inhibitory activity against Avian Pathogenic Escherichia coli multi-resistant strain.
• the compounds with general formula I represent medications, mainly medications against bacterial infections and are used in the treatment of bacterial infections.
• the bacterial infections that compounds with general formula I, especially 1 -amino- tetratriacontyl-henicosa-20-on-21 -al,successfully treat are:
• anthrax bacterial meningitis, brucellosis, bubonic plague, diphtheria, epidemic typhus, gonorrhoea, whooping cough (pertussis), campylobacteriosis, chlamydia (trachoma), cholera, plague, legionellosis, leprosy (Hansen's disease), leptospirosis in humans, leptospirosis, listeriosis, Lyme disease, melioidosis, nocardiosis, pneumonia, relapsing fever, psittacosis, q fever, salmonella, syphilis, MRSA infection, scarlet fever, shigellosis, tetanus, typhus, typhoid fever, tuberculosis, tularemia, rat-bite fever.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Pulmonology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
• Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (18)

Applications Claiming Priority (1)

Publications (1)

Family

ID=58530574

Family Applications (1)

Country Status (16)

Cited By (2)

Family Cites Families (1)

• 2017
  • 2017-02-21 WO PCT/HR2017/000002 patent/WO2018154344A1/en not_active Ceased
  • 2017-02-21 CA CA3053236A patent/CA3053236C/en active Active
  • 2017-02-21 AU AU2017399805A patent/AU2017399805B2/en active Active
  • 2017-02-21 RU RU2019126389A patent/RU2749376C1/ru active
  • 2017-02-21 CN CN201780087044.4A patent/CN110325245A/zh active Pending
  • 2017-02-21 DK DK17716587.5T patent/DK3598868T3/da active
  • 2017-02-21 PT PT177165875T patent/PT3598868T/pt unknown
  • 2017-02-21 KR KR1020197026606A patent/KR102296053B1/ko active Active
  • 2017-02-21 EP EP17716587.5A patent/EP3598868B1/en active Active
  • 2017-02-21 JP JP2019543913A patent/JP2020508297A/ja active Pending
  • 2017-02-21 PL PL17716587T patent/PL3598868T3/pl unknown
  • 2017-02-21 ES ES17716587T patent/ES2888948T3/es active Active
  • 2017-02-21 US US16/487,162 patent/US11180444B2/en active Active
  • 2017-02-21 HR HRP20211412TT patent/HRP20211412T1/hr unknown
  • 2017-02-21 SI SI201730887T patent/SI3598868T1/sl unknown
• 2019
  • 2019-08-26 ZA ZA2019/05612A patent/ZA201905612B/en unknown
• 2021
  • 2021-06-07 JP JP2021095156A patent/JP7101293B2/ja active Active

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events